Coordinated targeting of EGFR via CBD and TKIs could represent a logical approach for cancer treatment, particularly in HNSCC, where CBD receptors and EGFR signaling pathways interact [13]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.